The FDA database lists a supplement, dated 8 October 2026, to an abbreviated new drug application (ANDA 209051) for tafluprost held by Micro Labs. Tafluprost is a prostaglandin analogue used to lower intraocular pressure in open-angle glaucoma and ocular hypertension.
A supplement to a generic application is usually an administrative or manufacturing change — packaging, labelling, a manufacturing site or a specification — rather than a new indication or a safety finding. The record does not state what the supplement covers.
For prescribers there is no change in practice. The listing is a US regulatory action; Indian availability and CDSCO status are not addressed by it.
- This is a supplement to an existing generic tafluprost application, not a new approval.
- The record does not state the nature of the change.
- No change to tafluprost prescribing follows from this notice.
- Prostaglandin analogues remain a first-line option for lowering intraocular pressure.
Why it matters
Generic prostaglandin analogue supply affects the cost of lifelong glaucoma treatment.
Don't overread it
A supplement to a generic application is not a new indication or a safety signal.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free